Cargando…

T Cell Invigoration is Associated with the Clinical Response to Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer

PURPOSE: Immune checkpoint inhibitors (ICIs) have been developed for clinical application and proven effective for non-small cell lung cancer (NSCLC). Blockade of the programmed cell death 1 (PD-1) protein can partially reinvigorate circulating exhausted-phenotype CD8+ T cells (Tex cells) in preclin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Hui, Weng, Gui Zhen, Sun, Li Na, Pan, Zhang Chi, Zhang, Lu, Chen, Qiang, Shi, Chun Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10576507/ https://www.ncbi.nlm.nih.gov/pubmed/37842130 http://dx.doi.org/10.2147/CMAR.S415629

Ejemplares similares

LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Liu, Yi, et al.
Publicado: (2021)

Author Correction: LSD1 inhibition sustains T cell invigoration with a durable response to PD-1 blockade
por: Liu, Yi, et al.
Publicado: (2022)

An invigorated second term!
por: Nichani, Ashish Sham
Publicado: (2013)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

CNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer
por: Zhang, Biao, et al.
Publicado: (2020)

FBW7-mediated ubiquitination and destruction of PD-1 protein primes sensitivity to anti-PD-1 immunotherapy in non-small cell lung cancer
por: Liu, Jiaxin, et al.
Publicado: (2022)

The Anti-Inflammatory Effects of Invigorating Kidney and Supplementing Qi Chinese Herbal Formulae in Asthma Patients
por: Kong, Lingwen, et al.
Publicado: (2017)

The Lymph Node Microenvironment May Invigorate Cancer Cells With Enhanced Metastatic Capacities
por: Li, Tianhang, et al.
Publicado: (2022)

New Drugs, Appliances, and Things Medical: The Invigorator Corset
Publicado: (1892)

Molecular Mechanisms Underlying Qi-Invigorating Effects in Traditional Medicine: Network Pharmacology-Based Study on the Unique Functions of Qi-Invigorating Herb Group
por: Tran, Minh Nhat, et al.
Publicado: (2022)

Effect of Comorbidity on Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Undergoing Anti-PD1 Immunotherapy
por: Zeng, Xianghua, et al.
Publicado: (2020)

Lung Cancer Surgery after Treatment with Anti-PD1/PD-L1 Immunotherapy for Non-Small-Cell Lung Cancer: A Case—Cohort Study
por: El Husseini, Kinan, et al.
Publicado: (2021)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Peptide Adjuvant to Invigorate Cytolytic Activity of NK Cells in an Obese Mouse Cancer Model
por: Han, Seungmin, et al.
Publicado: (2021)

Nuclear AhR and membranous PD-L1 in predicting response of non-small cell lung cancer to PD-1 blockade
por: Han, Si-Chong, et al.
Publicado: (2023)

Achievement of long-term local control after radiation and anti-PD-1 immunotherapy in locally advanced non-small cell lung cancer
por: Jing, Zhao, et al.
Publicado: (2021)

Monitoring anti-PD-1-based immunotherapy in non-small cell lung cancer with FDG PET: introduction of iPERCIST
por: Goldfarb, Lucas, et al.
Publicado: (2019)

Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
por: Su, Chaoyue, et al.
Publicado: (2020)

Creative 52: weekly projects to invigorate your photography portfolio
por: Adler, Lindsay
Publicado: (2014)

Physical Methods for Seed Invigoration: Advantages and Challenges in Seed Technology
por: Araújo, Susana de Sousa, et al.
Publicado: (2016)

Immunological profiling as a means to invigorate personalized cancer therapy
por: Hegmans, Joost PJJ, et al.
Publicado: (2013)

Acetylcholine acts on songbird premotor circuitry to invigorate vocal output
por: Jaffe, Paul I, et al.
Publicado: (2020)

Call to action for an invigorated drive to scale up TB prevention
por: Kasaeva, T., et al.
Publicado: (2021)

Research Progress in the Effect of Traditional Chinese Medicine for Invigoration on Neurotransmitter Related Diseases
por: Zhang, Xiting, et al.
Publicado: (2018)

Fascaplysin Induces Apoptosis and Ferroptosis, and Enhances Anti-PD-1 Immunotherapy in Non-Small Cell Lung Cancer (NSCLC) by Promoting PD-L1 Expression
por: Luo, Lianxiang, et al.
Publicado: (2022)

Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
por: Mussafi, Ofek, et al.
Publicado: (2022)

Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer
por: Li, Yanping, et al.
Publicado: (2023)

Study on the Effect of Antiplatelet and Gastric Mucosal Protection of Traditional Chinese Medicine Invigorating Qi and Hemostasis
por: Zhang, Chen-Hao, et al.
Publicado: (2021)

Are anti-PD1 and anti-PD-L1 alike? The non-small-cell lung cancer paradigm
por: Banna, Giuseppe Luigi, et al.
Publicado: (2020)

Toxicities of Immunotherapy for Small Cell Lung Cancer
por: Fu, Yang, et al.
Publicado: (2021)

Anti‐PD1 versus anti‐PD‐L1 immunotherapy in first‐line therapy for advanced non‐small cell lung cancer: A systematic review and meta‐analysis
por: Brito, Angelo Borsarelli Carvalho, et al.
Publicado: (2021)

Progress in immunotherapy for small cell lung cancer
por: Zhao, Dong, et al.
Publicado: (2020)

Comparative Transcriptomic Analysis of Inarching Invigorating Rootstock onto Incompatible Grafts in Citrus
por: He, Wen, et al.
Publicado: (2022)

Determinants of survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 therapy
por: Ali, Wael Abdullah Sultan, et al.
Publicado: (2021)

Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Hwang, Sohyun, et al.
Publicado: (2020)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
por: Papadaki, Maria A, et al.
Publicado: (2020)

Regulatory (FoxP3(+)) T cells and TGF-β predict the response to anti-PD-1 immunotherapy in patients with non-small cell lung cancer
por: Koh, Jiae, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_8i64jtnknjg4ug7cngkljcub53